Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
16.22
+0.78 (5.05%)
At close: Jul 13, 2026, 4:00 PM EDT
16.20
-0.02 (-0.11%)
After-hours: Jul 13, 2026, 4:24 PM EDT
Mesoblast Employees
Mesoblast had 81 employees as of June 30, 2025. The number of employees increased by 8 or 10.96% compared to the previous year.
Employees
81
Change (1Y)
8
Growth (1Y)
10.96%
Revenue / Employee
$807,210
Profits / Employee
-$1,165,062
Market Cap
2.11B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 81 | 8 | 10.96% |
| Jun 30, 2024 | 73 | -10 | -12.05% |
| Jun 30, 2023 | 83 | 6 | 7.79% |
| Jun 30, 2022 | 77 | -6 | -7.23% |
| Jun 30, 2021 | 83 | -19 | -18.63% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Lakefront Biotherapeutics NV | 558 |
| Intellia Therapeutics | 377 |
| Nuvation Bio | 307 |
| Aurinia Pharmaceuticals | 128 |
| AnaptysBio | 104 |
| Nanobiotix | 100 |
| Taysha Gene Therapies | 99 |
MESO News
- 7 hours ago - Mesoblast reported Q4 Ryoncil net revenue of $36M - TheFly
- 9 hours ago - Mesoblast rises 6.2% - TheFly
- 3 days ago - Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 - GlobeNewsWire
- 4 days ago - Mesoblast Earnings release: Q4 2026 - Filings
- 12 days ago - Mesoblast (MESO) Secures FDA Filing for Rexlemestrocel-L Review - GuruFocus
- 12 days ago - Mesoblast receives BLA filing number from FDA for rexlemestrocel-L review - TheFly
- 12 days ago - Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs - GlobeNewsWire
- 18 days ago - Mesoblast Withdraws $50 Mln From Five-Year Non-Dilutive Facility - Nasdaq